Raptor Pharmaceutical Corp. To Present At The Stifel Nicolaus Healthcare Conference 2012

NOVATO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at the Stifel Nicolaus Healthcare Conference in Boston, MA at the Four Seasons Hotel. Raptor's presentation will take place on Thursday, September 6, 2012 beginning at 1:30 p.m. ET.

A live audio webcast and 14-day archive of the Stifel Nicolaus presentation will be available at http://ir.raptorpharma.com/events.cfm

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.

For additional information, please visit www.raptorpharma.com .

The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180
CONTACT: Trout Group (investors)         Lauren Glaser         (646) 378-2972         lglaser@troutgroup.com                  EVC Group (media)         Janine McCargo         (646) 688-0425         jmccargo@evcgroup.com

company logo